CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.
CytomX Therapeutics, Inc. (CTMX) on Monday announced encouraging early results from its Phase 1 expansion study of varsetatug masetecan (Varseta-M) in patients with late-line metastatic colorectal cancer (CRC).
The data, as of January 16, indicated the antibody-drug conjugate is showing meaningful response rates at optimized doses.
The CTMX-2051-101 trial, launched in April 2024, enrolled 93 heavily pretreated metastatic CRC patients, with 56 evaluable for efficacy across expansion doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg administered every three weeks. Confirmed response rates increased with dose; 6% at 7.2 mg/kg, 20% at 8.6 mg/kg, and 32% at 10 mg/kg.
Following the results, CytomX Therapeutics stock traded over 54% in Monday’s premarket.
Get updates to this developing story directly on Stocktwits.<